 SAN DIEGO, June 21, 2021 PRNewswire -- Regulus Therapeutics Inc . Nasdaq: RGLS, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs the Company or Regulus, today announced that it will present new preclinical data and additional clinical data from the first cohort of patients in the Companys Phase 1b clinical trial of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021, being held virtually Friday, June 25. 